SCHEMBL2383353

SCHEMBL2383353

CS(=O)(=O)OC[C@@H](Oc1ccc2ccccc2c1)[C@@H]1CO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
PPARG P37231 3/20 0.39
PPARA Q07869 3/20 0.39
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
L3MBTL1 Q9Y468 4/20 0.35
TDP1 Q9NUW8 2/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
POLB P06746 2/20 0.35
PTPN7 P35236 1/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
FAAH O00519 1/20 0.34
EPHX1 P07099 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383358 1.00 SLC6A2 (0.44) SLC6A2SLC6A4PPARGPPARACA1
SCHEMBL2383807 0.85 TDP1 (0.35) SLC6A2TDP1LMNACYP1A2
SCHEMBL2383804 0.85 TDP1 (0.35) SLC6A2TDP1LMNACYP1A2
SCHEMBL2386602 0.83 FFAR4 (0.39) PPARGFAAHEPHX1
SCHEMBL2386597 0.83 FFAR4 (0.39) PPARGFAAHEPHX1
SCHEMBL2383729 0.79 MEN1 (0.37) SLC6A2SLC6A4L3MBTL1RAB9AALDH1A1
SCHEMBL2383732 0.79 MEN1 (0.37) SLC6A2SLC6A4L3MBTL1RAB9AALDH1A1
SCHEMBL2385224 0.73 CA1 (0.37) SLC6A2SLC6A4CA1CA2CA9
SCHEMBL2385217 0.73 CA1 (0.37) SLC6A2SLC6A4CA1CA2CA9
SCHEMBL27844576 0.72 L3MBTL1 (0.41) PPARGPPARACA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 SLC6A2 4882/4885SLC6A4 4861/4885PPARG 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.